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years actuarial local control (LC) rates were 100% and 88%, 
respectively. Median overall survival (OS) was 24 months. 
Actuarial OS rates at 1 and 2 years were 83% and 38%, 
respectively. Median progression-free survival (PFS) was 7 
months. No patients experienced radiation-induced liver 
disease (RILD) or grade >3 toxicity. 
 
Conclusion: SABR is an effective, safe and non-invasive 
alternative for the treatment of inoperable liver metastases 
from radioresistant tumor. 
 
Electronic Poster: Clinical track: Lower GI (colon, rectum, 
anus)  
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Purpose or Objective: To compare the clinical outcomes 
between short course chemoradiotherapy (SCRT) and long 
course chemoradiotherapy (LCRT) with delayed surgery for 
locally advanced rectal cancer patients retrospectively. 
 
Material and Methods: Seventy two patients, staged cT3-
4N0-2M0, had participated in a multicenter study. With 
regard to the SCRT arm, a total dose of 25 Gy of radiotherapy 
was delivered in 5 fractions and chemotherapy was given on 
days 1-3 and delivered 5-Fluouracil and Leucovorin 
400mg/m²by bolus injection on day 1 and 5-Fluouracil 
1200mg/m²by continuous infusion on day 2 and 3. And 
additional two cycles of chemotherapy was administered 
before the surgery. With regard to the LCRT arm, a total dose 
of 50.4Gy of radiotherapy was delivered in 28 fractions. 
Chemotherapy was a bolus injection of 5-Fluouracil and 
leucovorin for the first and last week of radiotherapy. 
Surgery was performed during 6 - 8 weeks after completion of 
the radiotherapy in the both group. 
 
Results: From 2010 to 2015, 19 patients were treated using 
the SCRT and 53 patients were treated using the LCRT. 
Median Follow-up was 25.0 months (range, 3.0-58.0 months). 
The patient characteristics of the both arms were not 
significantly different. The sphincter saving rate (89.5 %, 
94.3%), complete remission (21.1%, 13.2%), downstaging 
(47.4%, 26.4%), treatment complications including wound 
dehiscence, bowel adhesion, hematologic toxicities of the 
SCRT were not inferior results to those of the LCRT. 
Locoregional recurrence was seen in 1 (5.3%) patients in the 
SCRT, 1 (1.9%) in the LCRT (p=0.442). Distant metastasis was 
ween in 1 (5.3%) patients in the SCRT, 12 (22.6%) patients in 
the LCRT (p=0.162). The 2-year disease free survival, overall 
survival in the SCRT and LCRT arms were 93.8% and 74.0% (P 
=0.338), 90.0% and 91.2% (P =0.448), respectively. 
 
Conclusion: The preopeative SCRT was a effective and safe 
modality. We got a comparable clinical outcomes to the LCRT 
for locally advanced rectal cancer. We get a further study for 
randomized clinical study to compare between SCRT and 
LCRT.  
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Purpose or Objective: Preoperative chemoradiation for 
rectal cancer may cause acute bowel toxicity. Efforts to 
reduce such side effects include tracking bowel DVH 
relationships and proper patient positioning to minimize the 
risks. Our aim is to quantify volume and DVH relationship 
differences between prone and supine positioning as well as 
compare different contouring methods to account for such 
changes. 
 
Material and Methods: Nineteen patients undergoing 
preoperative chemoradiation for rectal cancer were 
simulated supine and prone for plan comparison. Thirty-eight 
plans were compared, 19 prone, and 19 supine. Correlating 
prone and supine plans were constructed with similar target 
volumes, beam energies and arrangements. A single physician 
contoured the bowel bag (BB) and individual bowel loops (BL) 
with the superior border 1 cm above the PTV per RTOG 
guidelines. If the RTOG recommended boundaries fell short of 
the 5 Gy isodose line, additional CT slices were contoured on 
BB and BL structures to the 5 Gy isodose line and labeled as 
extended contours. Tabular dose-volume histograms were 
utilized to assess the volume of bowel receiving 5-50 Gy in 5 
Gy intervals. Wilcoxon signed rank test as well as Spearman’s 
correlation tested all variables. 
 
Results: The target volumes showed no statistical differences 
between supine and prone positioning (p = 0.7344, 0.8203, 
0.3594). The median reduction in volumes from supine to 
prone contours for the extended contour BB, extended 
contour BL, RTOG BB, and RTOG BL was 316 cc, 156 cc, 324 
cc, and 115 cc respectively. Wilcoxon signed rank sum test 
showed significantly reduced volumes at each dose level (5-
45 Gy at 5 Gy intervals) in the prone group compared to 
supine (range p = 0.0039- 0.0391). All combinations of 
contours (RTOG and extended contours of BB and BL) showed 
similar statistically significant reductions in volumes 
receiving each dose (except 50 Gy) in the prone position. All 
RTOG defined BB and BL volumes required additional 
contours to account for the entire volume receiving 5 Gy. 
RTOG contours required a median of 359 cc to the BB (range 
209-1375 cc) and 113 cc to BL (range 37-271 cc). 
 
Conclusion: Volume of bowel was less for nearly all dose 
levels (5 – 45 Gy) if the patient was positioned prone. Bowel 
loop contours correlated with bowel bag contours; suggesting 
they can be used interchangeably. BB and BL contoured 
volumes, by the RTOG definition, consistently fell short of 
the 5 Gy isodose line where the “extended contours” were a 
more complete DVH representation. 
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Purpose or Objective: The standard treatment for locally 
advanced rectal cancer (LARC) is preoperative 
chemoradiotherapy (CRT) followed by total mesorectal 
excision (TME). The tumoral response to CRT is highly 
heterogeneous and about 15-30% of the patients achieve a 
pathological complete response (pCR). 18F-FDG PET/CT is 
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promising in response prediction and a reduction in maximal 
standardized uptake value (SUVmax) has been correlated 
with therapy response. In a prospective study, we 
investigated whether PET-based response prediction improves 
with blood glucose level (BGL) normalization. 
 
Material and Methods: Eighty-five patients with LARC were 
treated with CRT (45 Gy in 1.8 Gy fractions, 5-FU 
(225mg/m²)) followed by TME after 6-8 weeks. Patients 
underwent 18F-FDG PET/CT scans at three time points: prior 
to CRT, after 10-12 fractions and prior to surgery. PET data 
were normalized to the BGL measured before FDG injection. 
Three normalization methods were compared: linear 
correction according to Janssen et al (SUVnormalized= 
SUVmax*(glycemia/100)), and two corrections suggested by 
Keramida et al (SUVnormalized = 
(SUVmax*glycemia)/SUVmeanliver and SUVnormalized = 
SUVmax*e(0.099*glycemia)). Treatment response was 
classified as pCR, ypT0-1 and ypT0-2. PET parameters were 
compared with pathological response using Mann-Whitney U 
tests. ROC analysis was employed to investigate the 
performance of the glycemia corrected and uncorrected PET 
parameters. A p-value ≤0.05 was considered statistically 
significant. 
 
Results: Thirteen patients achieved pCR while ypT0-1 and 
ypT0-2 response was observed in 23 and 50 patients 
respectively. While the value of PET obtained prior to 
(SUVmaxpre) and during (SUVmaxduring, RI SUVmaxduring) 
CRT was limited, presurgical scans (SUVmaxpost, RI 
SUVmaxpost) appeared useful for response prediction (see 
Table and Figure). The performance of PET-based response 
assessment increased with a less stringent definition of tumor 
response. There were no major differences in the predictive 
performance of PET-based response parameters before and 
after BGL normalization and between different normalization 
methods. 
 
 
 
 
 
Conclusion: Especially presurgical 18F-FDG PET/CT is useful 
for the prediction of the tumoral response to CRT in rectal 
cancer. Blood glucose level normalization has little effect on 
the performance of PET-based response prediction and there 
is no large difference in performance between normalization 
approaches.  
1 Janssen et al, Radiother Oncol 2010; 95(2):203-8. 
2 Keramida et al, Eur Radiol 2015; 25(9):2701-8. 
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Purpose or Objective: To investigate the outcomes of 
advanced anal carcinoma treated with radical Volumetric 
Modulated Arc Therapy (VMAT) chemoradiotherapy. 
 
Material and Methods: From January 2013 – March 2015, 
twenty patients (median age 64; Range 46-83; M:F 4:16) with 
advanced anal carcinoma (T3-T4 or N1-N3) were treated with 
radical VMAT chemoradiotherapy at our hospital.  
The clinical target volume (CTV) included the anal canal, 
primary tumour, mesorectum, presacral nodes, interior iliac 
nodes and inguinal nodes. All Patients were prescribed 
Mitomycin C (12mg/m2 D1; capped at 20mg) and 
capecitabine (600mg/m2 BD D1-14 and D22-35) 
chemotherapy concurrently with radiotherapy. 
 
Results: All patients had histologically confirmed squamous 
cell carcinoma. Treatment was completed in all patients. The 
standard dose prescription was 50.4Gy in 28 fractions for T3 
tumours (8 patients). T4 or node positive cancers received 
either a simultaneous integrated boost of 2.8Gy to a total 
dose of 53.2 Gy in 28 fractions (9 patients) or up to a further 
3 fractions to a maximum total dose of 56Gy (3pts).  
At time of analysis (Median follow up 22.3 months) one 
patient (5%) had a local recurrence and two patients (10%) 
had developed metastatic disease, all of which are currently 
being managed with palliative intent.  
The only significant toxicities recorded were local skin 
erythema and desquamation. Additionally one patient (5%) 
developed secondary myelodysplastic syndrome which was 
